ACR Joins Letter Urging $51.3 Billion for NIH in FY27
ACR urged Congress to provide at least $51.3 billion in funding for NIH in federal fiscal year 2027.
Read moreMain Content
ACR Congratulates Sirtex Medical on FDA Approval of Its SIR-Spheres to Treat Liver Cancer
The ACR-managed clinical trial was a key part of the approval effort.
Aug. 6, 2025
The ACR® Center for Research and Innovation (CRI®) served as the imaging contract research organization for the DOORwaY90 clinical trial that contributed to FDA approval of Sirtex SIR-Spheres technology for liver cancer treatment.
CRI’s management of image and data collection, quality control, and central review of 600 CT/MRI scans from 65 subjects across 12 sites using five expert reviewers was critical to the success of the trial.
Interim analysis of the DOORwaY90 trial revealed that 98.5% of patients had the Best Overall Response Rate through nine months and 100% of all evaluable patients were able to demonstrate local tumor control.
